Several major drugmakers, including Merck & Co. Inc. MRK and AstraZeneca PLC AZN, say they're moving forward with the Medicare drug-price negotiation process ahead of this Sunday's deadline to sign...

Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings p...

AstraZeneca, Boehringer Ingelheim and other drugmakers have filed at least eight lawsuits seeking to declare the Medicare price talks unconstitutional.

AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they're continuing to increase investment in the country

Shares of biopharmaceutical giant AstraZeneca (AZN) were upgraded to "Buy" from "Hold" at Jefferies. The analyst says assets outside of the company's oncology pipeline are being overlooked.

AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.

AstraZeneca PLC (LSE:AZN)'s assets beyond oncology offer significant upside potential, in the view of investment bank, Jefferies. The broker upgraded the pharmaceuticals giant to 'buy' from 'hold' ...

These are the stocks posting the largest moves in early trading.

Some might overlook AstraZeneca, but the stock has strong growth prospects. Eli Lilly continues to fire on all cylinders, with especially big opportunities for Mounjaro.

AstraZeneca (AZN) ADSs rose after reporting its experimental breast cancer treatment made with Japanese partner Daiichi Sankyo showed positive high-level results in a Phase 3 trial.

AstraZeneca PLC (LSE:AZN)'s share price surged by 2.6%, adding nearly £5 billion to the company's market value, following the announcement of encouraging results from an ongoing clinical trial on d...

AstraZeneca PLC (LSE:AZN) has hailed strong results from an ongoing trial on the effects of drug datopotamab deruxtecan in breast cancer patients. According to the pharmaceutical giant, the drug sh...

AstraZeneca said on Friday a drug it is developing with Daiichi Sankyo's to treat patients with a type of breast cancer met one of the main goals in a late-stage study.

AstraZeneca PLC (LSE:AZN) shares rose 2.4% to 10,868p after its Alexion rare disease unit sealed a deal to buy a portfolio of Pfizer's early-stage drugs to boost its footprint in the burgeoning fie...